66 results
8-K
EX-10.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
4 Nov 22
Unaudited Pro Forma Condensed Consolidated Financial Statements
4:08pm
on representations made by Remainco, Spinco, Parent, and their respective representatives, and not by independent review, and shall function only as an expert
425
6vylwy
24 Mar 22
Business combination disclosure
9:09am
8-K
EX-2.1
rwf f27hb5
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
8-K
EX-99.1
6h0sgbkflwazjdjo
29 Jul 21
Ligand Reports Second Quarter 2021 Financial Results
4:04pm
8-K
EX-2.1
duj4h9lysz
13 Oct 20
Entry into a Material Definitive Agreement
8:44am
8-K
EX-10.4
jn3rsu7q
10 Sep 20
Entry into a Material Definitive Agreement
4:43pm